Filtered By:
Therapy: Corticosteroid Therapy
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 18765 results found since Jan 2013.
Identifying clusters of coexisting conditions and outcomes among adults admitted to hospital with community-acquired pneumonia: a multicentre cohort study
We described differences in medications, imaging and outcomes.RESULTS: Patients clustered into 7 subgroups. The low comorbidity subgroup (n = 3052, 27.5%) had no comorbidities. The DM-HF-Pulm subgroup had prevalent diabetes, heart failure and chronic lung disease (n = 1710, 15.4%). One disease category defined each remaining subgroup, as follows: pulmonary (n = 1621, 14.6%), diabetes (n = 1281, 11.6%), heart failure (n = 1370, 12.4%), dementia (n = 1038, 9.4%) and cancer (n = 1013, 9.1%). Corticosteroid use ranged from 11.5% to 64.9% in the dementia and pulmonary subgroups, respectively. Piperacillin-tazobactam use ranged ...
Source: cmaj - September 5, 2023 Category: General Medicine Authors: Sarah L Malecki Hae Young Jung Anne Loffler Mark A Green Samir Gupta Derek MacFadden Nick Daneman Ross Upshur Michael Fralick Lauren Lapointe-Shaw Terence Tang Adina Weinerman Janice L Kwan Jessica J Liu Fahad Razak Amol A Verma Source Type: research
Smell improvement in chronic rhinosinusitis with nasal polyps with monoclonal antibodies: a systematic review
CONCLUSION: Dupilumab may have the highest efficacy in improving sense of smell, compared to omalizumab, mepolizumab and benralizumab.PMID:37669083 | DOI:10.18176/jiaci.0939
Source: Journal of Investigational Allergology and Clinical Immunology - September 5, 2023 Category: Allergy & Immunology Authors: B Barroso M Valverde-Monge D Betancor A G ómez-López C Villalobos-Vildas B Gonz ález-Cano J Sastre Source Type: research
SQ HDM sublingual immunotherapy tablet for the treatment of HDM allergic rhinitis and asthma improves subjective sleepiness and insomnia: an exploratory analysis of the real-life CARIOCA study
CONCLUSION: In patients with HDM AR and/or asthma associated sleep disorders, an improvement in subjective insomnia and sleepiness was observed after one year of treatment with the SQ HDM SLIT-tablet in a real-life setting.PMID:37669078 | DOI:10.18176/jiaci.0934
Source: Journal of Investigational Allergology and Clinical Immunology - September 5, 2023 Category: Allergy & Immunology Authors: D Jaffuel E Serrano C Leroyer A Chartier P Demoly Source Type: research
Smell improvement in chronic rhinosinusitis with nasal polyps with monoclonal antibodies: a systematic review
CONCLUSION: Dupilumab may have the highest efficacy in improving sense of smell, compared to omalizumab, mepolizumab and benralizumab.PMID:37669083 | DOI:10.18176/jiaci.0939
Source: Journal of Investigational Allergology and Clinical Immunology - September 5, 2023 Category: Allergy & Immunology Authors: B Barroso M Valverde-Monge D Betancor A G ómez-López C Villalobos-Vildas B Gonz ález-Cano J Sastre Source Type: research
SQ HDM sublingual immunotherapy tablet for the treatment of HDM allergic rhinitis and asthma improves subjective sleepiness and insomnia: an exploratory analysis of the real-life CARIOCA study
CONCLUSION: In patients with HDM AR and/or asthma associated sleep disorders, an improvement in subjective insomnia and sleepiness was observed after one year of treatment with the SQ HDM SLIT-tablet in a real-life setting.PMID:37669078 | DOI:10.18176/jiaci.0934
Source: Journal of Investigational Allergology and Clinical Immunology - September 5, 2023 Category: Allergy & Immunology Authors: D Jaffuel E Serrano C Leroyer A Chartier P Demoly Source Type: research
The chronic rhinosinusitis practice parameter
Ann Allergy Asthma Immunol. 2023 Sep;131(3):307-310. doi: 10.1016/j.anai.2022.12.022. Epub 2022 Dec 17.ABSTRACTThe Allergy-Immunology Joint Task Force on Practice Parameters has published the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) guidelines for the medical management of chronic rhinosinusitis with nasal polyposis (CRSwNP). The practice parameter provides evidence-based guidelines on the use of intranasal corticosteroids (INCS) and biologics for CRSwNP, and aspirin therapy after desensitization (ATAD) for the management of aspirin-exacerbated respiratory disease (AERD). Evidence on surge...
Source: Annals of Allergy, Asthma and Immunology - September 5, 2023 Category: Allergy & Immunology Authors: So Lim Kim Matthew A Rank Anju Tripathi Peters Source Type: research
No Difference Between One-shot Co-injection of Corticosteroids and Hyaluronic Acid in a Three-injection Regimen for Knee Osteoarthritis: A Randomized, Double-blind Trial
CONCLUSION: We found that a single co-injection of corticosteroids along with HA did not confer any additional benefit regarding patient-reported outcomes or physical function compared with a three-injection regimen of HA. Therefore, we do not recommend a one-shot co-injection of corticosteroids alongside the three-injection regimen of HA for patients with knee OA, and because prior research found HA to be ineffective, HA should not be used with or without corticosteroids for patients with knee OA.LEVEL OF EVIDENCE: Level I, therapeutic study.PMID:37669538 | DOI:10.1097/CORR.0000000000002793
Source: Clinical Orthopaedics and Related Research - September 5, 2023 Category: Orthopaedics Authors: Ru-Lan Hsieh Wen-Chung Lee Source Type: research
Identifying clusters of coexisting conditions and outcomes among adults admitted to hospital with community-acquired pneumonia: a multicentre cohort study
We described differences in medications, imaging and outcomes.RESULTS: Patients clustered into 7 subgroups. The low comorbidity subgroup (n = 3052, 27.5%) had no comorbidities. The DM-HF-Pulm subgroup had prevalent diabetes, heart failure and chronic lung disease (n = 1710, 15.4%). One disease category defined each remaining subgroup, as follows: pulmonary (n = 1621, 14.6%), diabetes (n = 1281, 11.6%), heart failure (n = 1370, 12.4%), dementia (n = 1038, 9.4%) and cancer (n = 1013, 9.1%). Corticosteroid use ranged from 11.5% to 64.9% in the dementia and pulmonary subgroups, respectively. Piperacillin-tazobactam use ranged ...
Source: cmaj - September 5, 2023 Category: General Medicine Authors: Sarah L Malecki Hae Young Jung Anne Loffler Mark A Green Samir Gupta Derek MacFadden Nick Daneman Ross Upshur Michael Fralick Lauren Lapointe-Shaw Terence Tang Adina Weinerman Janice L Kwan Jessica J Liu Fahad Razak Amol A Verma Source Type: research
The chronic rhinosinusitis practice parameter
Ann Allergy Asthma Immunol. 2023 Sep;131(3):307-310. doi: 10.1016/j.anai.2022.12.022. Epub 2022 Dec 17.ABSTRACTThe Allergy-Immunology Joint Task Force on Practice Parameters has published the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) guidelines for the medical management of chronic rhinosinusitis with nasal polyposis (CRSwNP). The practice parameter provides evidence-based guidelines on the use of intranasal corticosteroids (INCS) and biologics for CRSwNP, and aspirin therapy after desensitization (ATAD) for the management of aspirin-exacerbated respiratory disease (AERD). Evidence on surge...
Source: Annals of Allergy, Asthma and Immunology - September 5, 2023 Category: Allergy & Immunology Authors: So Lim Kim Matthew A Rank Anju Tripathi Peters Source Type: research
No Difference Between One-shot Co-injection of Corticosteroids and Hyaluronic Acid in a Three-injection Regimen for Knee Osteoarthritis: A Randomized, Double-blind Trial
CONCLUSION: We found that a single co-injection of corticosteroids along with HA did not confer any additional benefit regarding patient-reported outcomes or physical function compared with a three-injection regimen of HA. Therefore, we do not recommend a one-shot co-injection of corticosteroids alongside the three-injection regimen of HA for patients with knee OA, and because prior research found HA to be ineffective, HA should not be used with or without corticosteroids for patients with knee OA.LEVEL OF EVIDENCE: Level I, therapeutic study.PMID:37669538 | DOI:10.1097/CORR.0000000000002793
Source: Clinical Orthopaedics and Related Research - September 5, 2023 Category: Orthopaedics Authors: Ru-Lan Hsieh Wen-Chung Lee Source Type: research
SQ HDM sublingual immunotherapy tablet for the treatment of HDM allergic rhinitis and asthma improves subjective sleepiness and insomnia: an exploratory analysis of the real-life CARIOCA study
CONCLUSION: In patients with HDM AR and/or asthma associated sleep disorders, an improvement in subjective insomnia and sleepiness was observed after one year of treatment with the SQ HDM SLIT-tablet in a real-life setting.PMID:37669078 | DOI:10.18176/jiaci.0934
Source: Journal of Investigational Allergology and Clinical Immunology - September 5, 2023 Category: Allergy & Immunology Authors: D Jaffuel E Serrano C Leroyer A Chartier P Demoly Source Type: research
Identifying clusters of coexisting conditions and outcomes among adults admitted to hospital with community-acquired pneumonia: a multicentre cohort study
We described differences in medications, imaging and outcomes.RESULTS: Patients clustered into 7 subgroups. The low comorbidity subgroup (n = 3052, 27.5%) had no comorbidities. The DM-HF-Pulm subgroup had prevalent diabetes, heart failure and chronic lung disease (n = 1710, 15.4%). One disease category defined each remaining subgroup, as follows: pulmonary (n = 1621, 14.6%), diabetes (n = 1281, 11.6%), heart failure (n = 1370, 12.4%), dementia (n = 1038, 9.4%) and cancer (n = 1013, 9.1%). Corticosteroid use ranged from 11.5% to 64.9% in the dementia and pulmonary subgroups, respectively. Piperacillin-tazobactam use ranged ...
Source: cmaj - September 5, 2023 Category: General Medicine Authors: Sarah L Malecki Hae Young Jung Anne Loffler Mark A Green Samir Gupta Derek MacFadden Nick Daneman Ross Upshur Michael Fralick Lauren Lapointe-Shaw Terence Tang Adina Weinerman Janice L Kwan Jessica J Liu Fahad Razak Amol A Verma Source Type: research
